Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7539 1801

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542


Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

EvaluatePharma World Preview 2013, Outlook to 2018 - Returning to Growth


EvaluatePharma World Preview 2013 - Outlook to 2018

 Download EvaluatePharma World Preview 2013 Outlook to 2018 

In this sixth edition of EvaluatePharma's World Preview we once again bring together many of our analyses to provide a top level insight, from the world’s financial markets, into the expected performance of the industry between now and 2018.

In dollar terms, worldwide prescription ƒƒdrugs sales experienced an unprecedented fall of 1.6% in 2012 due to a large number of blockbuster patent expiries, however the latest edition of Evaluate's World Preview highlights that growth is expected to return from 2013 - view the report infographic here

Analysis Highlights include:

  • Worldwide prescription drug sales forecast to total $895bn in 2018 (CAGR: 3.8% 2012-2018)
  • Between 2013 and 2018, $230bn of sales at risk from patent expiration
  • Humira projected to be world’s largest selling product in 2018
  • Pfizer remains top company by worldwide prescription drug sales in 2012; Novartis number two
  • By 2018, Novartis expected to be number one, in terms of worldwide Rx sales
  • Worldwide pharmaceutical R&D spend forecast to be $149bn in 2018 (CAGR: 1.4% 2012-2018)
  • Gilead’s hepatitis C polymerase inhibitor, Sofosbuvir, remains the most valuable R&D product
  • Anti-coagulants set to record highest worldwide sales growth of major therapy categories to 2018 (CAGR: 11.5% 2012-2018)

Based on EvaluatePharma’s coverage of the world’s leading 4,000 pharmaceutical and biotech companies, the 39 page World Preview report highlights trends in Prescription Drug Sales, Patent Risk, R&D Spend, Global Brand Sales, Market Performance by Therapy Area...and a brief review of industry performance in 2012.

Download EvaluatePharma World Preview 2013 Outlook to 2018 

Report Executive Summary